Wang Kan

Mr. Wang Kan, aged 38, serves as the officer of the investment management department and the deputy officer of policy study office of China National Pharmaceutical Group Co., Ltd. Mr. Wang obtained a master’s degree of science in pharmacognosy from the School of Pharmaceutical Sciences of Peking University Health Science Center in July 2009. Mr. Wang successively worked at the planning development and industrial management department of China National Pharmaceutical Industry Corporation Ltd. and the investment management department and securities department of China National Biotec Group Co., Ltd. respectively from August 2009 to November 2014. Mr. Wang has worked for China National Pharmaceutical Group Co., Ltd. since November 2014 and held positions of the officer assistant and the deputy officer of the investment management department. He has been serving as the officer of the investment management department and the deputy officer of policy study office of China National Pharmaceutical Group Co., Ltd. since August 2021. At present, Mr. Wang also serves as the director of China National Biotec Group Co., Ltd., China Traditional Chinese Medicine Holdings Co. Limited, China National Corp. of Traditional and Herbal Medicine, Chongqing Taiji Industry (Group) Co., Ltd. and Fresenius Kabi Huarui Pharmaceutical Co., Ltd.